Pashtoon Murtaza Kasi, Manuel Hidalgo, Mehraneh D Jafari, Heather Yeo, Lea Lowenfeld, Uqba Khan, Alana T H Nguyen, Despina Siolas, Brandon Swed, Jini Hyun, Sahrish Khan, Madeleine Wood, Benjamin Samstein, Juan P Rocca, Allyson J Ocean, Elizabeta C Popa, Daniel H Hunt, Nikhil P Uppal, Kelly A Garrett, Alessio Pigazzi, Xi Kathy Zhou, Manish A Shah, Erika Hissong
In patients with locally advanced cancer without distant metastases, the neoadjuvant setting presents a platform to evaluate new drugs. For mismatch repair proficient/microsatellite stable (pMMR/MSS) colon and rectal cancer, immunotherapy has shown limited efficacy. Herein, we report exceptional responses observed with neoadjuvant botensilimab (BOT), an Fc-enhanced next-generation anti-CTLA-4 antibody, alongside balstilimab (BAL; an anti-PD-1 antibody) in two patients with pMMR/MSS colon and rectal cancer. The histological pattern of rapid immune response observed ("inside-out" (serosa-to-mucosa) tumor regression) has not been described previously in this setting...
September 21, 2023: Oncogene